Written Question · S6W-11807 · Session 6
What the cost would be of making the monoclonal antibody Evusheld available on prescription to NHS patients in Scotland who are immunocompr…
The question
To ask the Scottish Government what the cost would be of making the monoclonal antibody Evusheld available on prescription to NHS patients in Scotland who are immunocompromised and vulnerable to COVID-19.
The answer
The decision not to procure Evusheld ® at this time has been taken based on clinical advice, rather cost.
The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .
The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.
The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .
The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.
In the Official Report
No contribution in the Official Report cites S6W-11807 by reference.